Alliance Pharma plc

LSE APH.L

Alliance Pharma plc EBT Margin for the year ending December 31, 2023: -27.01%

Alliance Pharma plc EBT Margin is -27.01% for the year ending December 31, 2023, a -968.23% change year over year. EBT Ratio (Earnings Before Tax Ratio) is the fraction of earnings before taxes to total revenue, indicating the company's profitability before the impact of tax expenses.

Alliance Pharma plc EBT Margin for the year ending December 31, 2022 was 3.11%, a -72.04% change year over year.
Alliance Pharma plc EBT Margin for the year ending December 31, 2021 was 11.13%, a 10.94% change year over year.
Alliance Pharma plc EBT Margin for the year ending December 31, 2020 was 10.03%, a -56.23% change year over year.
Alliance Pharma plc EBT Margin for the year ending December 31, 2019 was 22.91%, a 18.77% change year over year.

Key data

Date	EBT Margin	Net Income Margin	EBITDA Margin	EBIT Margin

LSE: APH.L

Alliance Pharma plc

CEO	Mr. Nicholas John Sedgwick
IPO Date	Nov. 22, 2001
Location	United Kingdom
Headquarters	Avonbridge House
Employees	290
Sector	Healthcare
Industries Drugstores & Retail Pharmacies Consumer Packaged Goods Cosmetics Eyewear Perfumes & Fragrances Personal Care Pharmaceuticals

Description

Alliance Pharma plc operates as a pharmaceutical company in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. The company acquires, markets, and distributes consumer healthcare and prescription medicine products. It holds the marketing rights of approximately 80 consumer healthcare and prescription medicine products. The company also offers medical devices, food supplements, and cosmetics. Alliance Pharma plc provides its products under the Aloclair, Anbesol, Asthon and Parsons, Atopiclair, Forceval, Hydromol, Kelo-cote, Macushield, Vamousse, Nizoral, and Amberen brand names. The company was founded in 1996 and is headquartered in Chippenham, the United Kingdom.

Key trends

Past 5 years